To move advanced therapy medicinal products (ATMPs) from the lab to the commercial-scale manufacturing facility, you need a future-proof plan. These 6 questions will help you create one.Read More
Revolutionary insights for the next gen of medicine.
How to achieve a viral vector manufacturing facility at scale
Viral vector gene therapies, which harness modified viruses to deliver genetic material into target cells, offer promising therapeutic potential.Read More
What’s next for the life science industry?
Real talk from the front lines of today’s research and manufacturing landscapeRead More
Benefits of membrane filtration systems for ambient WFI production
The shift to membrane-based WFI production can significantly reduce utility use, shrink facility footprint requirements, and help meet corporate sustainability goals.Read More
The promise of RNA-based therapies
Decades of scientific progress in understanding the root cause of many formerly intractable diseases has opened up new treatment options, namely through RNA-based therapies. This second wave of biopharma, in which our understanding of the ways coding portions of our genome relate to disease, allows us to intercede earlier, and at more specific and effective junctures.Read More
An introduction to modern monoclonal antibody manufacturing
Monoclonal antibody (mAb) therapies continue to provide both powerful weapons against disease and compelling business opportunities for forward-thinking companies.Read More
Which is more sustainable: stainless steel or single-use systems?
What are the environmental impacts of single-use technology and stainless steel systems? And which should you use in your next facility?Read More
4 cell therapy manufacturing approaches: your guide to optimizing every square foot
Could your cell therapy manufacturing facility be working harder for you? If you have (or anticipate having) small-scale cell therapies in your pipeline, this question is vital.Read More
Expanding global operations with standard facility design
Increasingly, manufacturers want standard facility designs of their GMP manufacturing facilities so they can be replicated elsewhere in the world, but this approach comes with unique considerations.Read More
In-house production vs. CDMO: meeting the challenges of commercializing cell and gene therapies
Commercializing cell and gene therapies efficiently requires timely decisions about whether to engage a CDMO or develop internal manufacturing capacity. Sometimes the best solution is to do both.Read More